NCT02734615 - Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers | Biotech Hunter

Enrollment

199

Participants

Timeline

Start Date

June 14, 2016

Primary Completion Date

September 13, 2021

Study Completion Date

September 13, 2021

Conditions

Advanced or Metastatic ER+ Breast Cancer

Interventions

DRUG

LSZ102

DRUG

LEE011

DRUG

BYL719

Trial Locations (10)

Novartis Investigative Site, Brussels

Memorial Sloan Kettering Cancer Center, New York

Novartis Investigative Site, Milan

Novartis Investigative Site, Milan

Novartis Investigative Site, Lyon

MD Anderson Cancer Center SC - LSZ102X2101, Houston

Novartis Investigative Site, Ulm

Novartis Investigative Site, Singapore

Massachusetts General Hospital Massachusetts General Hospital, Boston

Novartis Investigative Site, Koto Ku